Navigation Links
Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
Date:1/16/2009

ANN ARBOR, Mich., Jan. 16 /PRNewswire/ -- Use of prescription sleep aids nearly tripled among 18- to 24-year-olds between 1998 and 2006, according to a study released today by the Healthcare business of Thomson Reuters.

During the study period, the average length of time sleep aids were used by adults under age 45 increased more than 40 percent -- rising from 64 days in 1998 to 93 days in 2006.

"Insomnia, a condition traditionally associated with older adults, appears to be causing larger numbers of young adults to turn to prescription sleep aids, and to depend on them for longer periods of time," said William Marder, PhD, senior vice president and general manager for the Healthcare business of Thomson Reuters.

The study is based on medical and drug claims data from the Thomson Reuters MarketScan(R) Research Databases. Results were weighted to reflect the U.S. population with employer-sponsored health insurance.

Researchers found a 50-percent increase in the use of prescription sleep aids among all adults under age 45 from 1998 to 2006. The most dramatic increase was seen in the youngest segment of the study population, those between the ages of 18 and 24, whose prevalence of use increased from 599 users per 100,000 in 1998 to 1,524 users per 100,000 in 2006. For those 25 to 34 years of age, use almost doubled from 1,372 users to 2,528 users per 100,000.

Non-benzodiazepine hypnotics -- such as Ambien CR and Lunesta -- accounted for almost two-thirds of all the prescription sleep aids used by this population.

A number of psychiatric, cognitive and conditioning factors are known to perpetuate insomnia, and the study found that 25 percent of first-time sleep aid users had a mental heath diagnosis in the month prior to sleep aid use. However, fewer than 10 percent of these new users visited a mental health professional prior to initiating sleep aid use. M
'/>"/>

SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Thomson Healthcare Cancer Profiler Used in Study
2. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
3. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
6. Study Shows How Defective DNA Repair Triggers Two Neurological Diseases
7. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
8. New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors
9. VA-NIH Study Offers Hope for Parkinsons Patients
10. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
11. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2012)... May 23, 2012 Medical Tactile, Inc. (MTI), ... Incorporated, today announced that they have developed a pre-commercial ... sensor technology for breast cancer screening.  ... Komen Foundation, 1.6 million women worldwide were diagnosed with ... the disease. Although early detection is the best means ...
(Date:5/23/2012)... Kraton Performance Polymers, Inc. (NYSE: "KRA"), ... or SBCs , and PolyOne Distribution, a ... and solutions, announce the execution of a distribution ... PolyOne product line. "Kraton Polymers ... IR products due to their deep knowledge about ...
(Date:5/23/2012)... 2012  Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical ... for its U.S. phase 2 clinical trial, T ... G reater E fficacy T rial ... in patients with non-tuberculous mycobacterial (NTM) lung disease. ... to support current NTM treatment recommendations, and no new ...
Breaking Medicine Technology:Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 2Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 3Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 4Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line 2Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 2Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 4Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 5Resource savvy communities generate healthy sustainable changes 15181 1Resource savvy communities generate healthy sustainable changes 15181 2Radiation Oncology Services of America Inc to Work With Washington University on Quality Assurance Initiative 10552 1Radiation Oncology Services of America Inc to Work With Washington University on Quality Assurance Initiative 10552 2U S Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014 10547 1U S Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014 10547 2
... Type 2 Diabetes Using Emisphere,s Eligen(R) ... ... Emisphere,Technologies, Inc. (Nasdaq: EMIS ) today announced findings from a ... study used a delivery-agent-based approach using Emisphere,s Eligen(R),technology, and was conducted ...
... meets primary endpoints in ENGAGE Trial, KENILWORTH, ... ) announced today that corifollitropin alfa, its,experimental, sustained ... Phase III ENGAGE trial, according to data presented ... of the,European Society of Human Reproduction and Embryology ...
Other Medicine Technology:Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 2Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 3Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant 2Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant 3
(Date:5/23/2012)... proteins of the same kind, thereby triggering skeletal and ... researchers from the RUB Heart and Diabetes Center NRW ... in an interdisciplinary research project with colleagues from the ... the Journal of Biological Chemistry . , ... forms stabilizing filaments inside of the cells. Different mutations ...
(Date:5/23/2012)... FRANCISCO Prior treatment with inhaled corticosteroids in ... pneumonia (CAP) is associated with a lower incidence ... new study from researchers in Spain. , A ... (excess fluid that accumulates between the two pleural ... that arises as a result of a pneumonia, ...
(Date:5/22/2012)... Bend Research Inc., a leading independent ... expansion of its existing hot-melt extrusion (HME) ... Leistritz twin-screw mixer/extruder. , The 18mm ... 27mm Leistritz and 19mm Baker Perkins extruder ... high-shear wet-granulation capabilities. Many projects have been ...
(Date:5/22/2012)... The uproar that began last year when the U.S. ... longer offer regular prostate-cancer tests to healthy men continued ... report. Overall, they stuck to their guns, stating that ... cancer, the PSA test, causes more harm than good ... even dangerous, treatments. , But many people simply don,t ...
(Date:5/22/2012)... , , TUESDAY, May 22 (HealthDay News) -- Two preliminary ... both the detection and treatment of pancreatic cancer. ... said they have fashioned a vaccine that, in early ... attacking cancer cells. The team -- from Case ... Cancer Center at University Hospitals Case Medical Center in ...
Breaking Medicine News(10 mins):Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Long-term ICS use reduces pleural effusion in patients with CAP 2Health News:Psychological Science explains uproar over prostate-cancer screenings 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 3Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 4
... 18 Women,s, health and,environmental groups today called on ... wake of product tests released last week by the,Campaign ... an,independent lab, 61 percent (20 samples) contained detectable levels ... lipsticks with the highest lead,content were made by L,Oreal ...
... Decisions Network,(MDN) announces Food and Drug Administration 510(k) ... The MDN-CGS software is used,by hospital nurses to ... administered to patients with elevated levels of blood,glucose, ... to energy for survival. More and more ...
... to Reduce Number Denied by President, a Few in ... 2,000,children will join the ranks of the uninsured, adding ... public health insurance,according to new data released today by ... new analysis, American Families Face Harsh Reality: 2,000 Children,Join ...
... Mass., Oct. 18 Yankee Candle Company,Inc., the ... home fragrance, is,taking action in the fight against ... Logo: http://www.newscom.com/cgi-bin/prnh/20071018/NYTH093LOGO-b ) Yankee Candle ... breast,cancer awareness and research. The company is donating ...
... returning U.S. veterans , , THURSDAY, Oct. 18 (HealthDay News) ... when deciding how best to treat post-traumatic stress disorder ... of the data concludes. , The Institute of Medicine ... Affairs, which noted that about 12.6 percent of personnel ...
... Haas (NYSE:,ROH) announced today that it has ... used as a bonding alternative for pressure,sensitive ... like,door panels, interior pillars, instrument panels and ... before seen or thought possible,in an aqueous ...
Other Medicine News:Health News:Health Groups Call on Cosmetic Giant L'Oreal to Remove Lead From Lipstick 2Health News:FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software 2Health News:Families Face Harsh Reality: 2,000 Children Join the Uninsured Each Day 2Health News:Yankee Candle Company Sheds Some Light In The Fight Against Breast Cancer 2Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 2Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 3Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 4Health News:New Water-Based Acrylic Pressure-Sensitive Adhesive Defeats Heat and Humidity Issue 2
The CapSureFix line of pacing leads combines the benefits of steroid-eluting technology with screw-in active fixation, to allow long-lasting, low-threshold delivery of pacing therapies....
... Physique leads are small profile endocardial permanent ... With a lead body size of only ... of 7 F, the Physique lead is ... today. Available in both straight and pre-formed ...
Used with permanent pacing leads....
...
Medicine Products: